News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Merrimack Pharmaceuticals Inc. to Present Preclinical Data on Bispecific Antibody MM-111 in ErbB2-Positive Gastric Cancers


1/23/2013 8:50:35 AM

CAMBRIDGE, Mass., Jan. 23, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) announced today that preclinical data regarding the bispecific antibody MM-111 will be presented at the American Society of Clinical Oncology 2013 Gastrointestinal Cancers Symposium (ASCO GI), January 24-26, 2013 in San Francisco.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES